DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of DBV Technologies in a report on Wednesday, February 21st.

DBV Technologies Stock Down 1.1 %

Shares of DBV Technologies stock opened at $0.78 on Wednesday. The firm has a market capitalization of $149.72 million, a P/E ratio of -1.99 and a beta of 0.76. The company has a 50 day moving average price of $0.85 and a 200 day moving average price of $0.97. DBV Technologies has a 52 week low of $0.65 and a 52 week high of $2.37.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.10. The firm had revenue of $8.88 million during the quarter, compared to analyst estimates of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. During the same period last year, the firm posted ($0.23) EPS. As a group, research analysts anticipate that DBV Technologies will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DBVT. Commonwealth Equity Services LLC acquired a new position in DBV Technologies in the third quarter valued at about $26,000. Two Sigma Investments LP boosted its position in shares of DBV Technologies by 80.9% during the 3rd quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock worth $64,000 after purchasing an additional 16,066 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of DBV Technologies by 43.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 54,497 shares of the company’s stock worth $83,000 after purchasing an additional 16,469 shares during the period. BNP Paribas Arbitrage SNC boosted its position in shares of DBV Technologies by 74.2% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 39,034 shares of the company’s stock worth $74,000 after purchasing an additional 16,626 shares during the period. Finally, BNP Paribas Arbitrage SA purchased a new position in shares of DBV Technologies during the 2nd quarter worth approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.